NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
View PDF of blog article here
Unless Congress acts to overrule the FDA, research disasters such as occurred in London, when six healthy men were exposed to an experimental substance that brought them close to death, are likely to occur with increased frequency.
At FDA, Graham is still the whistle-blower – USA Today Thu, 17 Nov 2005 On Nov. 18, 2004, Dr. David Graham, FDA’s associate director for science and medicine, blew the whistle in testimony before the Senate Finance Committee, on FDA’s “profound regulatory failure” to protect the public against lethal prescription…
WSJ: Debate Over Antidepressants: FDA role in suppressing damaging data Tue, 25 May 2004 How were drug manufacturers able to conceal vital evidence of harmful antidepressant drug effects? The answer is becoming clearer by the day: federal regulators and the psychiatrists who tested these drugs in clinical trials are invested…
FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post Thu, 18 Nov 2004 The Washington Post examines FDA’s record of surveillance and the evidence is clear: since 1992 when Congress required drug companies to pay users fees to the FDA, the agency’s focus changed from safety…
Sen Grassley to Offer Mandatory Drug Data Registry Bill Fri, 10 Dec 2004 AHRP applauds Senator Chuck Grassley for spearheading legislation that will require pharmaceutical companies to register ALL drug trials and report their results in a public database. Given the record of deception and concealment of adverse data, anything…
The New York Times reports that Federal prosecutors have issued a subpoena seeking information and all documents including transcripts of their testimony produced in litigation relating to three prominent Harvard researchers…